Skip to main content

Intraurethral Alprostadil

Intraurethral alprostadil — delivered via the Medicated Urethral System for Erection (MUSE) — is an FDA-approved second-line treatment for erectile dysfunction that offers a needle-free alternative to intracavernosal injection. Per the AUA ED guideline (2018), it is an option for men who have contraindications to PDE5 inhibitors, prefer not to take oral medication, or prefer not to use needles (Conditional Recommendation; Evidence Level: Grade C).[1] Real-world efficacy (43–69%) is lower than intracavernosal injection but is offset by better tolerability and acceptability — the MUSE vs ICI trade-off dominates every practical decision in this class.

For related classes, see Intracavernosal injection agents, PDE5 inhibitors, and Testosterone replacement.

Mechanism and delivery pharmacology​

Alprostadil is synthetic prostaglandin E1 (PGE1) — chemically identical to the endogenous compound. It activates EP receptors on cavernosal smooth muscle, raising intracellular cAMP, lowering intracellular calcium, and producing trabecular smooth-muscle relaxation with cavernosal arterial dilation and veno-occlusive activation.[2][3]

The intraurethral route works because the corpus spongiosum communicates with the corpora cavernosa via submucosal venous channels; drug absorbed across urethral mucosa reaches the corpora by this retrograde venous transfer.[3] Urethral columnar epithelium absorbs more efficiently than keratinized skin, but absorption is still far less efficient than direct intracavernosal delivery — intraurethral doses (125–1000 µg) are 15–30× higher than intracavernosal doses (2–60 µg) to achieve clinically meaningful effect.[3]

Despite the higher administered dose, intraurethral delivery produces less priapism, less fibrosis, and fewer hematomas than intracavernosal injection because local-tissue concentrations are lower and drug distribution is more diffuse.[3]

The MUSE delivery device​

The MUSE applicator is a polypropylene device with a hollow stem 3.2 cm long and 3.5 mm in diameter; the tip carries a semisolid alprostadil pellet suspended in polyethylene glycol.[3][4]

Administration technique​

  1. Urinate immediately before application — residual urine lubricates applicator insertion and facilitates dispersion of the pellet[3]
  2. Insert the applicator stem fully into the urethra
  3. Depress the button to deposit the pellet
  4. Remove the applicator
  5. Roll the penis gently between the hands for 30–60 seconds to distribute the medication
  6. Erection typically begins in 5–10 minutes and lasts 30–60 minutes[3][4]

Dosing and titration​

MUSE is available in 125, 250, 500, and 1000 µg pellets.[3][5]

StepPractical
Starting dose500 µg — Ekman 2000 RCT showed starting at 500 µg raised in-clinic intercourse-sufficient erection from 28% → 60% vs 250 µg, without serious dose-related systemic AEs[5][4]
Most-used dose in pivotal trial1000 µg (41% of successful responders) — 500 µg in 30%; lower doses less common[3]
Real-world distribution500 µg in 49.2% and 1000 µg in 42.2% of successful users[6]
Maximum frequency2 administrations per 24 h; no more than 7 per week per FDA label[4]
In-office titrationRequired before home use per AUA Clinical Principle[1]

Efficacy — pivotal trial and real-world​

Padma-Nathan 1997 (NEJM pivotal trial, n = 1,511)[3]​

  • In-clinic: 65.9% achieved erections sufficient for intercourse (Erection Assessment Scale 4–5) with at least one dose
  • At-home (3-month double-blind phase, n = 461 randomized to alprostadil): 64.9% had ≥1 successful intercourse vs 18.6% placebo (p < 0.001)
  • Study completion 88% in a selected, motivated population

Cross-trial meta-analysis (3 RCTs, n = 1,828) confirmed the headline signal: 65% vs 18% placebo for ≥1 successful intercourse episode.[2]

Real-world — a more nuanced picture​

StudynSettingSuccessContinuation / notesRef
Padma-Nathan 1997 pivotal1,511Multicenter RCT65.9% clinic / 64.9% home88% study completion[3]
Ekman 2000166Randomized open-label68% (≥1 intercourse)500 µg starting recommended[5]
Guay 2000270Retrospective56%Higher doses and patient education critical[6]
Kim 2000 (Korea)334Multicenter59.3% clinic / 78.1% home86.9% continuation[7]
Khan 2002 (UK)100Clinical practice35% initialOnly 43% of responders at 6 months[8]
Fulgham 1998115Urology practice13–30% in-office>80% discontinued at home[9]

The discrepancy between trial and real-world results is large. In the Fulgham urology-practice cohort, >80% discontinued due to pain, insufficient erections, and cost. In the Khan UK series, only ~15% were long-term users (35% initial success × 43% continuation at 6 months).[8][9]

Adverse effects and safety profile​

The safety advantage over ICI is the defining feature of this route.[3]

AEPivotal trial rateNotes
Penile pain35.7% clinic / 32.7% home (after 10.8% of doses)Usually mild; only 2.4% discontinued for pain
Hypotension3.3% clinic (dose-dependent: 0.5% at 125 µg → 2.4% at 1000 µg)Higher in real-world cohort where 41.2% had orthostasis during in-office testing by strict criteria[9]
Syncope0.4% clinic, none at homeMonitor during in-office titration
Minor urethral trauma5.1%Typically superficial abrasion with a drop of blood at the meatus
Dizziness1.9% at home
UTIRare
PriapismNone in pivotal trialMajor advantage over ICI
Penile fibrosisNone in pivotal trialMajor advantage over ICI
Urethral strictureNoneLong-term signal remains low

Partner effects​

Vaginal burning or itching in ~5.8% of female partners, presumed to be alprostadil transfer during intercourse; resolves with condom use.[4]

Contraindications​

  • Urethral stricture or obstruction
  • Urethritis, balanitis
  • Priapism history or conditions predisposing to priapism — SCD / trait, multiple myeloma, thrombocytopenia, polycythemia, leukemia
  • Penile implant or prior penile reconstructive surgery
  • Hypersensitivity to alprostadil
  • Sexual intercourse with a pregnant partner without condom — alprostadil may be harmful to the fetus
  • Paraplegia / quadriplegia were exclusion criteria in the pivotal trial — see SCI section below[2][3]

MUSE vs intracavernosal injection — the central trade-off​

Shabsigh 2000 randomized crossover multicenter study (n = 111) comparing Edex (ICI alprostadil) vs MUSE + optional ACTIS band:[10]

OutcomeICI (Edex)MUSE + ACTISp
Intercourse-sufficient erection per dose82.5%53.0%0.0001
Patients achieving ≥1 intercourse-sufficient erection92.6%61.8%0.0001
Patients achieving ≥75% intercourse-sufficient erections75.0%36.8%0.0001
Patient / partner preferencePreferred——

Shokeir 1999 prospective RCT (n = 60) confirmed ICI superiority on efficacy (90% vs 60% clinic; 87% vs 53% home) but found MUSE easier to administer (90% vs 40% "easy") with less penile pain (7% vs 47%). Withdrawal: 67% ICI vs 17% MUSE — the acceptability trade-off is real and important.[11]

Combination strategies​

ACTIS constriction band​

The ACTIS (Adjustable Constriction Therapy for Impotence System) band is placed at the base of the penis before MUSE administration to:[5][12]

  • Retain drug in the corpora (reduces venous outflow)
  • Improve rigidity of the induced erection
  • Reduce systemic absorption and hypotension risk

In Ekman's dose-optimization work, adding a constriction band rescued an additional 8% of patients who did not respond to 1000 µg alone.[5] In SCI patients, the constriction band is essential to prevent hypotension — transient hypotension occurred in all initial SCI patients tested without it.[12]

MUSE + PDE5 inhibitor​

Combining intraurethral alprostadil with a PDE5i exploits synergistic pharmacodynamics (PGE1-driven cAMP elevation + PDE5-inhibitor-driven cGMP preservation):[13][4]

  • MUSE salvage: effective in up to 43% of sildenafil non-responders[2]
  • Moncada 2018 review of 9 PDE5i + alprostadil combination studies — consistent IIEF improvement over monotherapy including post-prostatectomy ED; AEs did not drive discontinuation[13]
  • Garrido-Abad 2022 prospective n = 170 PDE5i non-responders — topical alprostadil + PDE5i improved IIEF-5 12.4 → 17.1 (p < 0.05)[14]
  • Porst 2013 SOP: Level 3 evidence that PDE5i + transurethral PGE1 outperforms either monotherapy[15]

Special populations​

Post-radical prostatectomy​

A well-established niche:[16][17]

  • Costabile 1998 retrospective analysis of the pivotal-trial post-RP subgroup (n = 384) — 70.3% achieved intercourse-sufficient erection in clinic, 57.1% had intercourse at home (overall 40.1%); no priapism, fibrosis, or UTI; hypotension lower than in other ED populations (0.8% vs 4.2%) but urethral pain higher (18.3% vs 10.4%)[16]
  • McCullough 2010 first large randomized penile-rehabilitation RCT (n = 212 bilateral nerve-sparing RP) comparing nightly intraurethral alprostadil vs nightly sildenafil — no significant differences in IIEF-EF or intercourse success; nightly subtherapeutic MUSE was well tolerated[17]
  • ACS Prostate Cancer Survivorship Guidelines list intraurethral dissolvable prostaglandin pellet as a treatment option when PDE5i fail or are not tolerated[18]

Spinal cord injury​

Limited efficacy; not the go-to option in this population:[12][19]

  • Bodner 1999 (n = 15 SCI) — MUSE produced less rigid erections than ICI in all patients; 12/15 achieved only grade 1–3; all 3 patients who tried MUSE at home were dissatisfied and returned to ICI
  • Constriction ring is mandatory in SCI to prevent hypotension
  • Better candidates: intact sensation and incomplete injuries; often ineffective in complete SCI
  • Variable effectiveness in intermittent catheterization users[19]

Diabetic ED​

Alprostadil — both routes — has a particular role in diabetic ED, which is the most common cause of PDE5i failure.[20]

Discontinuation — the dominant clinical problem​

Mirrors the ICI pattern but with different drivers:[6][8][9]

  • Khan UK series — only ~15% long-term users
  • Fulgham urology-practice — >80% discontinued at home (pain, insufficient erections, cost)
  • Primary reasons: insufficient efficacy 61.4%, side effects 38.6% (genital pain or urethral bleeding dominant)[6]
  • Pivotal trial 88% completion reflects a highly selected, motivated population, not typical real-world practice

Comparison across alprostadil formulations​

FormulationRouteDose rangeReal-world efficacyAdvantagesDisadvantages
MUSEIntraurethral pellet125–1000 µg43–69%Needle-free; no priapism/fibrosis in pivotal data; easy to learnLower efficacy than ICI; penile pain; hypotension; cost; partner effects[1][2]
Caverject / EdexIntracavernosal injection2–60 µg~70% monotherapy; ~90% TriMixHighest efficacy; predictable responseNeedle required; fibrosis 3–8%; priapism up to 4%; pain 29–35%[10][11]
Topical alprostadil (Vitaros / Virirec)Meatal cream300 µgVariableNon-invasive; no applicatorApproved only in Canada / EU; limited comparative data[14]

Evidence Summary​

IndicationEvidence levelKey sourceNotes
ED second-lineLevel 1AUA 2018[1]; Padma-Nathan 1997[3]65% vs 18% placebo
Starting dose 500 µgLevel 1Ekman 2000 RCT[5]28% → 60% vs 250 µg
ICI > MUSE on efficacyLevel 1Shabsigh 2000[10]; Shokeir 1999[11]82.5% vs 53% per-dose intercourse
MUSE better tolerability / lower withdrawalLevel 1Shokeir 1999[11]17% vs 67% withdrawal
MUSE + PDE5i combinationLevel 3Moncada 2018[13]; Garrido-Abad 2022[14]Salvage up to 43% of PDE5i non-responders
Post-RP rehabilitationLevel 2McCullough 2010 RCT[17]; Costabile 1998[16]Comparable to nightly sildenafil
ACTIS band benefitLevel 2Ekman 2000[5]; Bodner 1999[12]8% additional response; essential in SCI

Clinical Positioning​

  • MUSE is AUA second-line ED therapy alongside ICI — the choice between them is driven by patient preference, dexterity, needle tolerance, and willingness to trade efficacy for convenience.[1][10][11]
  • Start at 500 µg, not 250 µg. Ekman 2000 doubled intercourse-sufficient response without a meaningful AE penalty.[5]
  • Always do an in-office titration first. Required by AUA Clinical Principle — screens for hypotension, trains technique, calibrates expectations.[1]
  • Urinate immediately before administration — it's the single most important technique detail patients miss.[3]
  • ACTIS band rescues ~8% additional responders and is mandatory in SCI patients for hypotension prevention.[5][12]
  • Combine with PDE5 inhibitor for salvage — up to 43% of sildenafil non-responders respond to the combination.[2][13]
  • Expect significant discontinuation. Trial completion 88%, real-world continuation 15–40%. Plan follow-up to address pain, efficacy, and cost before patients silently drop off.[6][8][9]
  • No priapism and no fibrosis in the pivotal trial — the core safety argument for MUSE over ICI. Use it when these complications would be especially devastating.[3]
  • Counsel about partner effects — ~5.8% of female partners report vaginal burning/itching; condoms eliminate transfer.[4]
  • Post-RP rehabilitation with nightly subtherapeutic MUSE is comparable to nightly sildenafil in McCullough 2010 — a legitimate option particularly when PDE5i are contraindicated.[17]
  • In SCI, MUSE is weaker than ICI and hypotension risk is higher — prefer ICI with adequate counseling, reserve MUSE for motivated incomplete-SCI patients with intact sensation.[12][19]

See Also​

References​

1. Burnett AL, Nehra A, Breau RH, et al. "Erectile dysfunction: AUA guideline." J Urol. 2018;200(3):633–641. doi:10.1016/j.juro.2018.05.004

2. McVary KT. "Erectile dysfunction." N Engl J Med. 2007;357(24):2472–2481. doi:10.1056/NEJMcp067261

3. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. "Treatment of men with erectile dysfunction with transurethral alprostadil." N Engl J Med. 1997;336(1):1–7. doi:10.1056/NEJM199701023360101

4. Costa P, Potempa AJ. "Intraurethral alprostadil for erectile dysfunction: a review of the literature." Drugs. 2012;72(17):2243–2254. doi:10.2165/11641380-000000000-00000

5. Ekman P, Sjögren L, Englund G, Persson BE. "Optimizing the therapeutic approach of transurethral alprostadil." BJU Int. 2000;86(1):68–74. doi:10.1046/j.1464-410x.2000.00723.x

6. Guay AT, Perez JB, Velásquez E, Newton RA, Jacobson JP. "Clinical experience with intraurethral alprostadil (MUSE) in the treatment of men with erectile dysfunction: a retrospective study." Eur Urol. 2000;38(6):671–676. doi:10.1159/000020360

7. Kim SC, Ahn TY, Choi HK, et al. "Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea." Int J Impot Res. 2000;12(2):97–101. doi:10.1038/sj.ijir.3900490

8. Khan MA, Raistrick M, Mikhailidis DP, Morgan RJ. "MUSE: clinical experience." Curr Med Res Opin. 2002;18(2):64–67. doi:10.1185/030079902125000318

9. Fulgham PF, Cochran JS, Denman JL, et al. "Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting." J Urol. 1998;160(6 Pt 1):2041–2046. doi:10.1097/00005392-199812010-00028

10. Shabsigh R, Padma-Nathan H, Gittleman M, et al. "Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study." Urology. 2000;55(1):109–113. doi:10.1016/s0090-4295(99)00442-2

11. Shokeir AA, Alserafi MA, Mutabagani H. "Intracavernosal versus intraurethral alprostadil: a prospective randomized study." BJU Int. 1999;83(7):812–815. doi:10.1046/j.1464-410x.1999.00021.x

12. Bodner DR, Haas CA, Krueger B, Seftel AD. "Intraurethral alprostadil for treatment of erectile dysfunction in patients with spinal cord injury." Urology. 1999;53(1):199–202. doi:10.1016/s0090-4295(98)00435-x

13. Moncada I, Martinez-Salamanca J, Ruiz-Castañe E, Romero J. "Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil." Int J Impot Res. 2018;30(5):203–208. doi:10.1038/s41443-018-0046-2

14. Garrido-Abad P, Senra-Bravo I, Manfredi C, et al. "Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study." Int J Impot Res. 2022;34(2):164–171. doi:10.1038/s41443-020-00400-9

15. Porst H, Burnett A, Brock G, et al. "SOP conservative (medical and mechanical) treatment of erectile dysfunction." J Sex Med. 2013;10(1):130–171. doi:10.1111/jsm.12023

16. Costabile RA, Spevak M, Fishman IJ, et al. "Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy." J Urol. 1998;160(4):1325–1328.

17. McCullough AR, Hellstrom WG, Wang R, et al. "Recovery of erectile function after nerve-sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate." J Urol. 2010;183(6):2451–2456. doi:10.1016/j.juro.2010.01.062

18. Skolarus TA, Wolf AM, Erb NL, et al. "American Cancer Society prostate cancer survivorship care guidelines." CA Cancer J Clin. 2014;64(4):225–249. doi:10.3322/caac.21234

19. Hough S, Cordes CC, Goetz LL, et al. "A primary care provider's guide to sexual health for individuals with spinal cord injury." Top Spinal Cord Inj Rehabil. 2020;26(3):144–151. doi:10.46292/sci2603-144

20. Hanchanale V, Eardley I. "Alprostadil for the treatment of impotence." Expert Opin Pharmacother. 2014;15(3):421–428. doi:10.1517/14656566.2014.873789